Reconciliation of IP

Reconciliation of IP - Axcellant

Reconciliation of IP

  1. lut 28, 2025

What Does the 'Reconciliation of IP’ Mean?

Reconciliation of IP, in clinical research, refers to the process of accounting for all investigational product (IP) throughout a clinical trial. This involves tracking the quantity of IP received, dispensed, returned, and destroyed, ensuring that all units are accounted for and any discrepancies are identified and explained.

The reconciliation process is crucial for maintaining regulatory compliance and ensuring the integrity of clinical trial data. It typically occurs at regular intervals during the study and at the conclusion of the trial, with the aim of verifying that the IP has been handled and administered according to the study protocol.

Why Is the 'Reconciliation of IP’ Important in Clinical Research?

Reconciliation of IP is crucial for maintaining the integrity and validity of clinical trial data. It ensures that all investigational products are properly accounted for, which is essential for regulatory compliance and the accurate assessment of drug efficacy and safety.

This process also helps in detecting and preventing potential errors or misconduct in drug handling and administration. By providing a clear audit trail, reconciliation of IP supports the overall quality and credibility of the clinical research, which is vital for the eventual approval and marketing of new drugs.

Good Practices and Procedures

  1. Implement a barcode or RFID system for real-time tracking of IP units throughout the supply chain
  2. Conduct blind counts by independent monitors to verify site-reported IP quantities
  3. Utilize temperature-logging devices to ensure proper storage conditions and flag potential deviations
  4. Perform periodic cross-checks between electronic data capture systems and physical inventory logs
  5. Establish a standardized reconciliation schedule with increasing frequency as the study progresses

Related Terms

Resources

Axcellant at ICNC Berlin: Following the Future of Nuclear Cardiology – and helping bring it to clinical reality

The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…

Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…

One trial is no longer enough. Regulators on both sides of the Atlantic are building a new model of clinical evidence

The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…